Treatment of palmoplantar psoriasis with infliximab: A randomized, double-blind placebo-controlled study

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 12, 2011, Pages 1402-1408

  Bissonnette, R ^a   Poulin, Y ^b   Guenther, L ^c   Lynde, C W ^d   Bolduc, C ^a   Nigen, S ^a  

^a INNOVADERM RESEARCH   (Canada)

^b Centre Dermatologique du Québec Métropolitain   (Canada)

^c Guenther Dermatology Research Centre   (Canada)

^d Lynderm Research Inc Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO;

ADULT; ARTICLE; BODY SURFACE; CELLULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOT SOLE; FRACTURE; HAND PALM; HEPATITIS; HUMAN; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIBODIES, MONOCLONAL; CANADA; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOOT; HAND; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; PSORIASIS;

EID: 81155128660     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.03984.x     Document Type: Article

References (11)

1. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
2. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-31.e15.
3. Brunasso AMG, Salvini C, Massone C,. Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients. J Eur Acad Dermatol Venereol 2009; 23: 415-419.
4. Farley E, Masrour S, McKey J, et al. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009; 60: 1024-1031.
5. Wahie S, Alexandroff A, Reynolds NJ,. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 2006; 31: 460-461.
6. Fairhurst DA, Sheehan-Dare R,. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis. Clin Exp Dermatol 2009; 34: 421-422.
7. Carlsen KM, Riis L, Madsen OR,. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009; 28: 1001-1003.
8. Heymann WR,. Tumor necrosis factor inhibitor-induced pustular psoriasis? J Am Acad Dermatol 2007; 56: 327-329. (Pubitemid 46074257)
9. Michaelsson G, Kajermo U, Michaelsson A, et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005; 153: 1243-1244. (Pubitemid 41779595)
10. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223-231. (Pubitemid 46294587)
11. Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 2008; 7: 940-946.